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Summary
Fechtner syndrome is an autosomal-dominant variant of
Alport syndrome, manifested by nephritis, sensorineural
hearing loss, cataract formation, macrothrombocyto-
penia, and polymorphonuclear inclusion bodies. As op-
posed to autosomal-recessive and X-linked Alport syn-
dromes, which have been genetically well studied, the
genetic basis of Fechtner syndrome remains elusive. We
have mapped the disease-causing gene to the long arm
of chromosome 22 in an extended Israeli family with
Fechtner syndrome plus impaired liver functions and hy-
percholesterolemia in some individuals. Six markers
from chromosome 22q yielded a LOD score 13.00. A
maximum two-point LOD score of 7.02 was obtained
with the marker D22S283 at a recombination fraction
of 0. Recombination analysis placed the disease-causing
gene in a 5.5-Mb interval between the markers D22S284
and D22S1167. No collagen genes or genes comprising
the basement membrane have been mapped to this
region.
Introduction
In 1927, Alport first described the syndrome (MIM
153640) that bears his name (Alport 1927). This syn-
drome consists of progressive nephropathy, sensorineu-
ral hearing loss, and, in many cases, eye abnormalities
such as lenticonus or retinal anomalies. Electron-micro-
scopic investigations in the early 1970s identified the
thick and irregular glomerular basement membrane as
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the site of primary renal abnormality (Spear and Slusser
1972; Churg et al. 1973). Spear (1973) later suggested
that the association between the three target-organ pa-
thologies stemmed from an abnormality in a structural
gene that governs the composition of the basement
membrane in the glomerulus, lens capsule, and inner ear.
Recent studies have shown that mutations may occur at
any of several loci involved in basement-membrane type
IV–collagen synthesis.
Both mapping of the Alport loci to specific chromo-
somes and cloning of the different collagen type IV genes
have shown that COL4A1 and COL4A2 are located
close together on chromosome 13q33-34 (Boyd et al.
1988). COL4A3 and COL4A4 are located on chro-
mosome 2q35-37 (Mariyama et al. 1992), and COL4A5
and COL4A6 are located on the X chromosome (Hos-
tikka et al. 1990; Myers et al. 1990). Most patients have
an X-linked, dominant form of Alport syndrome that
arises from a mutation at the COL4A5 locus (Boye et
al. 1991; Netzer et al. 1992; Nakazato et al. 1993; No-
mura et al. 1993; Tryggvason et al. 1993). In others,
mutations and deletions in COL4A5 and COL4A6 cause
a combination of Alport syndrome and leiomyomatosis
(Antignac et al. 1992; Zhou et al. 1993; Heidet et al.
1995). The autosomal-recessive form results from mu-
tations at the COL4A3 or the COL4A4 locus (Lemmink
et al. 1994; Mochizuki et al. 1994). A much less frequent
and less characterized condition is the autosomal-dom-
inant form of disease that manifests itself in two forms.
(1) Classic Alport syndrome—Jefferson et al. (1997) re-
ported a linkage of a large dominant pedigree to the
chromosome 2 COL4A3-COL4A4 locus; no mutations
in these genes were found in the affected members of
the family. (2) A form that resembles Alport syndrome
in its renal, auditory, and ophthalmic manifesta-
tions—however, unique hematological features, which
include macrothrombocytopenia and typical cytoplas-
matic polymorphonuclear inclusion bodies sometimes
distinguish it from the classic Alport syndrome. These
hematological manifestations resemble those seen in the
Figure 1 Pedigree and typing for eight chromosome 22 markers. Circles represent females, and squares represent males; unblackened symbols denote unaffected individuals, and blackened
symbols denote affected individuals. Critical recombinations in individuals II-5, III-5, III-11, IV-3, and IV-7 define a 4-2-4-4-2-5 haplotype that is coinherited with the disease and that is not shared
by the unaffected family members.
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Table 1
Clinical Characteristics of Patients Affected with Fechtner Syndrome
Patient
Age
(years)
Macrothrombocytopenia
 Inclusion Bodies Deafness
Eye
Abnormalities Nephropathy
Impaired
Liver Function Hypercholesterolemia
IV1 17      
IV3 15      
IV4 6      
IV7 18      
IV8 18      
IV9 13      
III3 50      
III5 45      
III10 40      
III11 43      
III13 44      
II3 62      
II5 74      
II7 72      
II9 70      
II10 55      
NOTE.—A plus sign () denotes presence; a minus sign () denotes absence.
May-Hegglin anomaly, which also has an autosomal-
dominant mode of inheritance (Hegglin 1945). The mo-
lecular basis of these syndromes, also named “Fechtner”
(Peterson et al. 1985; MIM 153640) or “Epstein” (Ep-
stein et al. 1972; MIM 153650) syndromes, remained
elusive. In 1988, Gershoni-Baruch et al. (1988) described
a large family in which affected members had a com-
bination of nephropathy, eye abnormalities, high-tone
sensorineural hearing loss, impaired liver functions, hy-
percholesterolemia, macrothrombocytopenia, and poly-
morphonuclear inclusion bodies. Within this family, the
disease segregated in an autosomal-dominant mode. We
have recently identified additional family members and
have used this family to map the first autosomal-dom-
inant “Alport-like” disease.
Subjects and Methods
Patients and Family Members
The study included 38 individuals, 17 of whom were
affected (fig. 1). All patients had macrothrombocyto-
penia and polymorphonuclear inclusion bodies. They
also had various combinations of nephropathy, eye ab-
normalities, high-tone sensorineural hearing loss, im-
paired liver functions and hypercholesterolemia. The
clinical characteristics of the patients affected by Fecht-
ner syndrome are described in table 1. Patients were
recruited in Israel, Belgium, and the United States. In
each country, the appropriate institutional review board
approved the study, and informed consent was obtained
from all participants. Each subject underwent a full
physical and ophthalmologic examination, a hearing
test, a complete blood count, kidney- and liver-function
tests, a lipid profile, and Giemsa staining, under a light
microscope, for the study of platelets and polymorpho-
nuclear inclusion bodies.
Genotyping
DNA was extracted from whole blood according to
a standard phenol-chloroform protocol (Miller et al.
1988). A genomewide search was performed with the
CHLC/Weber Human Screening set 8/8RG of polymor-
phic markers.Markers specifically described in this study
include D22S1167, D22S689, D22S281, D22S685,
D22S691, D22S683, D22S283, and D22S284 (Genome
database). PCR reactions were done in a 15-ml reaction
volume containing 150 ng of genomic DNA, 10 pmol
of each unlabeled primer, 1.5 mM dNTPs (dCTP de-
pleted), 0.1 mCi dCTP32, 1.5 mM MgCl2, 0.5 U Taq
polymerase (Bioline UK), and PCR buffer containing
160 mM (NH4)SO4, 670 mM Tris HCl (pH 8.8), and
0.1% Tween 20. After an initial denaturation for 5 min
at 94C, 35 cycles were performed (94C for 30 s, 55C
for 30 s, and 72C for 30 s), followed by a final extension
time for 5 min at 72C. Samples were mixed with 10 ml
of loading buffer, denatured at 94C for 3 min, and
electrophoresed on 6% denaturing polyacrylamide gel.
Linkage Analysis
Linkage was calculated with the LINKAGE package
of computer programs (version 5.1; Lathrop et al. 1984).
Patients with macrothrombocytopenia and polymor-
phonuclear inclusion bodies, with or without any other
manifestations of the syndrome, were considered to be
affected. The trait was assumed to be autosomal dom-
inant, with a disease-allele frequency of .001 and pen-
1714 Am. J. Hum. Genet. 65:1711–1717, 1999
Figure 2 Schematic map of the interval containing the disease gene on chromosome 22. The markers are illustrated on the right.
etrance of 1.00. Allele frequencies for the different mi-
crosatellite markers were obtained from 38 normal
control individuals of Iraqi-Jewish origin (DNA supplied
by the Genetic Department of the Sackler School ofMed-
icine, Tel-Aviv University) and from the noncarrier chro-
mosomes in this family.
Results
Eleven of 16 patients evaluated had mild hypercho-
lesterolemia, with a mean value of 298 mg/100 ml, com-
pared with a value of 165 mg/100 ml in the nonaffected
members of the family ( ). There were typicallyP ! .05
high levels of LDL cholesterol and normal levels of HDL
cholesterol. None of the patients had a nephrotic syn-
drome that could explain the hypercholesterolemia.
Nine of 16 patients evaluated had mildly impaired liver
functions: mean aspartate aminotransferase was 80 mg/
100 ml ( ), and mean alanine aminotransferasewasn ! 40
91 mg/100 ml ( ).n ! 40
Polymorphic microsatellite repeats from chromo-
somes 2q35-37 and 13q33-34 enabled us to rule out
COL4A1, COL4A2, COL4A3, and COL4A4 as the dis-
ease-causing genes in this family. COL4A5 and COL4A6
reside on the X chromosome and therefore were not
considered to be candidate genes in this family.
In a subsequent genomewide search using 1100 mi-
crosatellites, linkage was detected with chromosome 22
markers. A schematic map of the region is shown in
figure 2. Six markers from the long arm of chromosome
22 showed an LOD score 13.00. Pairwise LOD scores
between Fechtner syndrome and chromosome 22 mark-
ers are presented in table 2. A maximum two-point LOD
score (Zmax) of 7.02 was obtained with marker D22S283
at a maximum recombination fraction (v) of 0. LOD-
score calculations were performedwith allele frequencies
derived from 38 normal control individuals of Iraqi or-
igin and from the noncarrier chromosomes of individ-
uals in this family. We repeated the calculations for all
markers, using published allele frequencies and equal
allele frequencies. In all cases, LOD scores were robust
to these changes in allele frequencies. Figure 1 shows
typing results for this family, with eight chromosome 22
markers. Two recombinant events in affected family
members (II-5 and III-11) established D22S284 as the
telomeric boundary of the interval, whereas one such
recombination (in individual III-5) defined D22S1167 as
the centromeric boundary. No recombination events
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Table 2
Two-Point LOD Scores between Fechtner Syndrome and Chromosome 22 Markers
MARKER
LOD SCORE AT v =
.00 .05 .10 .15 .20 .25 .30 vmax Zmax
D22S284  7.65 4.63 2.99 1.93 1.20 .69 .48 .01
D22S283 7.02 6.44 5.84 5.20 4.53 3.81 3.06 .00 7.02
D22S691 6.11 5.74 5.29 4.77 4.19 3.56 2.87 .00 6.11
D22S685 4.82 4.42 3.99 3.55 3.07 2.57 2.03 .00 4.82
D22S683 6.00 5.50 4.97 4.42 3.84 3.23 2.59 .00 6.00
D22S281 6.92 6.37 5.78 5.16 4.50 3.80 3.05 .00 6.92
D22S689 6.17 5.64 5.08 4.50 3.89 3.25 2.58 .00 6.17
D22S1167  3.14 3.04 2.79 2.47 2.09 1.67 .05 3.14
Table 3
Clinical Manifestations of the Various Alport-Like Syndromes
Syndrome and Inheritance Mutated Gene/Locus
Macro-
thrombo-
cytopenia
Inclusion
Bodies
Nephro-
pathy Deafness
Eye
Abnor-
malities
Impaired
Liver
Function
Hyper-
cholester-
olemia
Alport
X-linked COL4A5, COL4A6       
Autosomal recessive COL4A3, COL4A4       
Autosomal dominant COL4A3(?), COL4A4(?)       
May-Hegglin
Autosomal dominant ?  a     
Epstein
Autosomal dominant ?       
Fechtnerb
Autosomal dominant Chromosome 22q11-13  a     
Sebastian
Autosomal dominant ?  a     
a The three families with Fechtner syndrome that have been described so far differ slightly from each other, as described in the text.
b The ultrastructure of the inclusion bodies in Fechtner syndrome resemble those in Sebastian syndrome and are different from those seen
in the May-Hegglin anomaly.
were detected with six other markers within this interval.
Thus, the disease-causing gene maps to an 18-cM in-
terval between markers D22S284 and D22S1167. Ac-
cording to established physical maps, this interval spans
5.5 Mb.
Discussion
We have demonstrated that, in the family described
above, the disease-causing gene maps to chromosome
22q. Six markers on the long arm of chromosome 22
gave an LOD score 13.00. Haplotype analysis placed
the disease gene in a 5.5-Mb interval between D22S284
and D22S1167.
During the last 3 decades, a number of families sharing
Alport-like features and an autosomal-dominant mode
of inheritance have been reported. A comparison be-
tween these families, the X-linked and recessive forms
of Alport syndrome, is illustrated in table 3. Peterson et
al. (1985) reported a four-generation family in which
eight members had various combinations of nephritis,
sensorineural hearing loss, congenital cataracts, ma-
crothrombocytopenia, and cytoplasmatic polymorpho-
nuclear inclusion bodies. They named the syndrome
“Fechtner” after the index family. The inclusion bodies
were similar to those seen, under a light microscope, in
the May-Hegglin anomaly; however, under electron mi-
croscopy, they were found to contain spread filaments,
ribosomes, and some segments of rough and smooth
endoplasmatic reticulum. Gershoni-Baruch et al. (1988)
reported a second family, with 16 affected individuals.
These individuals resembled those described by Peterson
et al., but, in addition, they had impaired liver functions
and hypercholesterolemia. Rocca et al. (1993) described
a third family with very similar symptoms. Epstein syn-
drome is yet another closely related condition, which
manifests differently from the conditions of the families
described above by the lack of polymorphonuclear in-
clusion bodies (Epstein et al. 1972; Eckstein et al. 1975;
Bernheim et al. 1976; Parsa et al. 1976; Clare et al.
1979). No mutations in COL4A5 were found in two
Japanese patients with this syndrome (Kawai et al.
1995). Sebastian platelet syndrome shares the hemato-
logical manifestations of Fechtner syndrome but lacks
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its renal, auditory, and ophthalmologic findings (Grein-
acher et al. 1990). It is currently unknown, for most of
the autosomal-dominant families presented in table 2,
whether the disease-causing gene maps to chromosomes
2, 13, or 22 or to other, yet-undetermined loci.
An update of the data presented by Gershoni-Baruch
et al. (1988) shows more convincingly that there is a
progressive deterioration of all tissues involved in the
disease. The children usually present with hematological
manifestations, whereas the adults show the full-blown
phenotype by the 5th decade.
Other congenital disorders may be associated with
macrothrombocytopenia or inclusion bodies in the neu-
trophils. The gene coding for glycoprotein 1b-b, local-
ized in chromosome 22q11.2 (a few million bases from
the area containing the disease-causing gene in our fam-
ily), was recently found to be deleted in another ma-
crothrombocytopenic state, Bernard-Soulier syndrome
(Budarf et al. 1995; MIM 231200). The gene for Che-
diak-Higashi syndrome immune deficiency, character-
ized by inclusion bodies made of giant lysosomes in the
granulocytes in addition to partial oculocutaneous al-
binism, was localized to 1q42-43 (Barrat et al. 1996).
It may be hypothesized that the Fechtner gene is similar
or homologous to one of these genes.
The 5.5-Mb interval on chromosome 22q, to which
the disease-causing gene maps, contains 91 known
genes, none of which encode collagen. Moreover, none
of them encode a protein that is part of a basement
membrane, such as laminin, entactin, heparin sulfate
proteoglycans, or other glycoproteins, that may be ex-
pressed in a wide variety of tissues and that could ac-
count for the diverse symptomatology and labora-
tory abnormalities seen in Fechtner syndrome. This re-
gion, however, also contains 60 expressed-sequence tags,
whose function and tissue expression are unknown. Al-
though Fechtner syndrome is very rare, the wide variety
of tissues involved in this disease suggests that the clon-
ing of this gene may have a bearing on the understanding
of other genetic and nongenetic diseases in which these
specific tissues are involved.
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